IQVIA (NYSE:IQV) Receives New Coverage from Analysts at Redburn Atlantic

Redburn Atlantic assumed coverage on shares of IQVIA (NYSE:IQV) in a report published on Monday, Marketbeat.com reports. The brokerage issued a buy rating and a $276.00 price target on the medical research company’s stock.

Several other equities analysts have also commented on IQV. Royal Bank of Canada assumed coverage on IQVIA in a research report on Wednesday, September 4th. They set an outperform rating and a $275.00 price objective for the company. Morgan Stanley lifted their price target on IQVIA from $270.00 to $280.00 and gave the stock an overweight rating in a research report on Tuesday, July 23rd. StockNews.com lowered IQVIA from a buy rating to a hold rating in a research report on Friday, September 27th. Barclays lifted their price target on IQVIA from $255.00 to $275.00 and gave the stock an overweight rating in a research report on Tuesday, July 23rd. Finally, Evercore ISI lowered their price target on IQVIA from $270.00 to $265.00 and set an outperform rating for the company in a research report on Tuesday, October 8th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average target price of $268.87.

IQVIA Stock Performance

Shares of IQV stock opened at $233.22 on Monday. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The firm has a market capitalization of $42.49 billion, a price-to-earnings ratio of 31.86, a PEG ratio of 2.18 and a beta of 1.49. The stock has a fifty day moving average of $239.15 and a 200 day moving average of $231.46. IQVIA has a 52 week low of $167.42 and a 52 week high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.22 earnings per share. As a group, research analysts expect that IQVIA will post 10.25 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

A number of large investors have recently made changes to their positions in the company. Park Place Capital Corp purchased a new position in shares of IQVIA during the 3rd quarter valued at about $28,000. Rise Advisors LLC purchased a new position in shares of IQVIA during the 1st quarter valued at about $31,000. Versant Capital Management Inc lifted its position in shares of IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares in the last quarter. Riverview Trust Co purchased a new position in shares of IQVIA during the 1st quarter valued at about $32,000. Finally, Opal Wealth Advisors LLC purchased a new position in shares of IQVIA during the 2nd quarter valued at about $27,000. 89.62% of the stock is currently owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.